EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Intech Biopharm Ltd (6461) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Intech Biopharm Ltd TWD 10.82, price TWD 23.80, upside -54.6%, quality 26 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · TW · ISIN TW0006461007

IB Thin data Sep 24, 2026

Intech Biopharm Ltd

6461 · TWO

Weakest SetupStrongly overvalued and low quality.

!Fair value 10.82 TWD · Strongly overvalued (−55%)
!Quality 26/100
!Expensive Growth (revenue 5y +38.5 %/yr)
!Moderate debt · negative free cash flow
!Trails peers (2/8)
!Narrow moat 12/100
!Evidence only low, so the estimate is less certain
Watch Intech Biopharm Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

73.07 TWD 23.28 TWD Fair Value 10.82 TWD May 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 23.28 TWD – 73.07 TWD · fair‑value band 8.07 TWD – 16.13 TWD · the 23.80 TWD price screens above the 10.82 TWD fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Intech Biopharm in your weekly email

Every Wednesday you see whether Intech Biopharm is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform for treating asthma and COPD; and dry powder inhaler, a product comprises of blisters and capsules.

Show more

Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform for treating asthma and COPD; and dry powder inhaler, a product comprises of blisters and capsules. The company offers its products under the SYN006, SYN010, SYN007, Synflutide, Duasma, Synvent, and SYN011 names. Intech Biopharm Corporation was founded in 2010 and is headquartered in Taipei, Taiwan.

Stock analysis

Intech Biopharm Ltd (6461) currently trades at 23.80 TWD, while our model-based Fair Value estimate is 10.82 TWD, implying the stock looks roughly 120.1% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 8.07 TWD (bear) to 16.13 TWD (bull), the price of 23.80 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Intech Biopharm Ltd reported revenue of 108M TWD in FY2025 versus 38.9M TWD in FY2021, a compound +28.9%/yr. Reported net income was −389M TWD in FY2025.

Key figures

Market cap 1.8B TWD (≈ $55.9M) · P/S ratio 36.7 · EPS (TTM) −2.90 TWD · Return on equity −47.6% · Return on assets (EBIT) −12.9% · Operating margin −517% · Revenue (TTM) 48.6M TWD · Revenue growth (YoY) −78.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).

What moves the price

The share trades about 41% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −55%, 6461 screens richer than that median.

Fair Value models

Bear 8.07 TWD Fair Value 10.82 TWD Bull 16.13 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 4.99 TWD 6.69 TWD 9.98 TWD 54
All 1 models by family
Asset-Based
NCAV (Graham) 4.99 TWD 6.69 TWD 9.98 TWD 54

Open the full fair value analysis →

Notify me when 6461 reaches fair value

Put 6461 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 26/100

Of which business quality 26 · Market factors (momentum, volatility) 31

Profitability 0
Margins and returns on capital today
Quality Growth 81
Are margins and returns improving?
Cashflow 10
Earnings quality: real cash, not paper profit
Fin. Strength 29
Balance sheet, leverage, solvency risk
Investment 63
Disciplined investing over empire-building
Low Volatility 64
Calm price path (market factor)
Momentum 24
Price trend over the last 3–12 months (market factor)
52W Momentum 6
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+170.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+65.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+38.5%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,106.6% (2020) → −339.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6461 screens 120% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare Intech Biopharm Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 649 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 26 · Bottom 25%
Fair Value upside −55% · Below median
Profitability
Return on assets −12% · Below median
Growth and dividend
Revenue growth −79% · Bottom 25%
Balance sheet
Debt / equity 0.90× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.05× · Cheapest 25%
P/S (TTM) 1.15× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)55 · sector 97
DIVIDEND (yield)0 · sector 23

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $516.34 $567.97 +10%
Regeneron Pharmaceuticals, Inc REGN $801.82 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.12 A$197.03 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Intech Biopharm Ltd · Fair Value
10.82 TWD −120%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Intech Biopharm Ltd Fair Value". https://www.fairvalue-calculator.com/stock/6461

Frequently asked questions

Is Intech Biopharm Ltd (6461) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 10.82 TWD versus a price of 23.80 TWD, about −55% upside (overvalued).
What is the fair value of 6461?
Our model-based fair value for Intech Biopharm Ltd is 10.82 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 23.80 TWD.
What is the quality score of 6461?
Intech Biopharm Ltd has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Intech Biopharm Ltd (6461)?
Our model-based price target is the fair value of 10.82 TWD (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 8.07 TWD, optimistic scenario 16.13 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Intech Biopharm Ltd stock forecast for 2026?
Our models put fair value at 10.82 TWD, about −55% upside versus a price of 23.80 TWD (overvalued). Cautious scenario 8.07 TWD, optimistic scenario 16.13 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Intech Biopharm Ltd (6461)?
Intech Biopharm Ltd reported trailing-twelve-month revenue of about 48.6M TWD (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Intech Biopharm Ltd (6461)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Intech Biopharm Ltd it is 10.82 TWD per share (as of Sep 24, 2026), against a price of 23.80 TWD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Intech Biopharm Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 6461 trades above its calculated fair value: price 23.80 TWD, fair value 10.82 TWD, a gap of about −55% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6461?
No. The price is what the market pays today (23.80 TWD); the fair value is what the company's own numbers justify (10.82 TWD). For Intech Biopharm Ltd the two are 12.99 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Intech Biopharm Ltd worth?
The market values Intech Biopharm Ltd at about 1.8B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 23.80 TWD; our models calculate a fair value of 10.82 TWD per share.
What do the bullish and bearish scenarios say about 6461?
Our models span a range for Intech Biopharm Ltd: cautious scenario 8.07 TWD, base 10.82 TWD, optimistic 16.13 TWD per share (as of Sep 24, 2026, price 23.80 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Intech Biopharm Ltd (6461)?
Balance-sheet figures for Intech Biopharm Ltd (as of Sep 24, 2026): return on equity −47.6%, debt of 0.90 per unit of equity. They feed the Quality Score of 26/100, which measures business quality independently of the share price.
How far is 6461 from its 52-week high?
Intech Biopharm Ltd trades at 23.80 TWD, about 41% below its 52-week high of 40.50 TWD and 2% above the low of 23.28 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 10.82 TWD is for.
Which stocks are comparable to Intech Biopharm Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Intech Biopharm Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 23.80 TWD, calculated fair value 10.82 TWD (−55%), Quality Score 26/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6461 calculated?
We run Intech Biopharm Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 10.82 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Intech Biopharm Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Intech Biopharm Ltd (6461)?
The closing price on Sep 24, 2026 was 23.80 TWD. Our model-based fair value is 10.82 TWD, about −55% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Intech Biopharm Ltd right now?
The price sits above even our optimistic bull case (16.13 TWD). The favourable scenario is already priced in. Weak quality (26/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (8.07 TWD to 16.13 TWD) leaves room in how you read the outcome.

Key figures of Intech Biopharm Ltd

How large is the market capitalisation of Intech Biopharm Ltd (6461)?
The market capitalisation of Intech Biopharm Ltd is 1.8B TWD (≈ $55.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Intech Biopharm Ltd (6461)?
The price-to-sales ratio of Intech Biopharm Ltd is 36.7 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Intech Biopharm Ltd (6461)?
Earnings per share at Intech Biopharm Ltd are −2.90 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Intech Biopharm Ltd (6461)?
The return on equity (ROE) of Intech Biopharm Ltd is −47.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Intech Biopharm Ltd (6461)?
On an EBIT basis the return on assets of Intech Biopharm Ltd is −12.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Intech Biopharm Ltd (6461)?
The operating margin of Intech Biopharm Ltd is −517% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Intech Biopharm Ltd (6461)?
Revenue at Intech Biopharm Ltd is growing −78.5% versus a year earlier (3y avg +65.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Intech Biopharm Ltd (6461) generate?
The free cash flow of Intech Biopharm Ltd is −425M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Intech Biopharm Ltd (6461) carry?
The net debt of Intech Biopharm Ltd is 1.2B TWD (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Intech Biopharm Ltd in the live analysis

One click puts Intech Biopharm Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.